Podcasts about mounjaro

Send us a textSeason 3 Episode 4In this episode, we sit down with Karen Gilbert, an inspiring woman who has transformed her life through determination, research, and a thoughtful, professional approach to weight loss. Karen opens up about her personal journey—sharing the trials and tribulations she faced while struggling with her weight, and how she ultimately decided to try Mounjaro, a groundbreaking weight loss injection.Before taking this step, Karen invested countless hours into understanding the science behind the medication, consulting with healthcare professionals, and weighing up both the potential benefits and the possible risks. She candidly reveals the fears and doubts she had, the support systems she leaned on, and the disciplined mindset that guided her decision.Her story is not just about losing weight—it's about taking control, doing the research, and making informed choices. If you've ever wondered what it's really like to embark on a weight loss journey using medical intervention, this honest and empowering conversation will give you insight, hope, and perhaps the encouragement you've been looking for.#HeartTransplant#eatingdisorder#RareCondition#HealthJourney#LifeChangingDiagnosis#MentalHealth#Vulnerability#SelfCompassion#PostTraumaticGrowth#MedicalMiracle#BBCSports#Inspiration#Cardiology#Surgery#Podcast#Healthcare#HeartHealth#MedicalBreakthrough#EmotionalJourney#SupportSystem#HealthcareHeroes#PatientStories#CardiologyCare#MedicalJourney#LifeLessons#MentalWellness#HealthAwareness#InspirationalTalk#LivingWithIllness#RareDiseaseAwareness#SharingIsCaring#MedicalSupport#BBCReporter#HeartDisease#PodcastInterview#HealthTalk#Empowerment#Wellbeing#HealthPodcast#Harryhill#weightloss#MounjaroCheck out our website at www.whostomanddick.com

GLP-1 medications like Ozempic®, Wegovy®, or Mounjaro® can be powerful tools for appetite control and weight loss-but here's the truth no one's talking about: without strength training, you risk losing valuable muscle right along with the fat.In this episode, I break down why lifting weights is non-negotiable for women over 40 using GLP-1s. You'll learn:The science behind how these medications impact your body.The hidden danger of muscle loss and slowed metabolism.How strength training protects your long-term health, bone density, and fat loss results.Exactly what kind of workouts women should focus on to stay strong, energized, and confident.If you're ready to move beyond the scale and truly transform your body, this episode is your guide.Join us in the Inspire Fitness program: Use the link here: https://inspirehw.com/ Follow me on Instagram: https://www.instagram.com/fit.nutritionist?igsh=MTJqZXhjODR2ZzduaA%3D%3D&utm_source=qr Follow me on Facebook: https://www.facebook.com/Casey.Young.RD.CPT?mibextid=LQQJ4d

⁠Assessoria esportiva online e cursos⁠⁠⁠⁠⁠ | ⁠⁠⁠⁠⁠E-book "Dieta Inteligente - Para Perder Gordura e Ganhar Massa Muscular" – só R$ 39,90⁠⁠⁠⁠⁠ | ⁠⁠⁠⁠⁠Curso de Treino – Monte seu próprio treino ainda hoje⁠⁠⁠⁠⁠ | ⁠⁠⁠⁠⁠Curso de Emagrecimento – Como emagrecer e nunca mais engordar ⁠⁠⁠⁠⁠| ⁠⁠⁠⁠⁠Curso Sobre Esteroides Anabolizantes – Não use esteroides antes de fazer este curso ⁠⁠⁠⁠⁠| ⁠⁠⁠⁠⁠Curso de Suplementação para Praticantes de Musculação⁠⁠⁠⁠⁠ | ⁠⁠⁠⁠⁠Grupo do Telegram com promoções⁠⁠⁠⁠⁠ | ⁠⁠⁠⁠⁠Instagram⁠⁠⁠⁠⁠ | ⁠⁠⁠⁠⁠Facebook⁠⁠⁠⁠⁠ | ⁠⁠⁠⁠⁠Growth⁠⁠⁠⁠⁠ | ⁠⁠⁠⁠⁠Oficialfarma⁠

En este episodio hablo con el Dr. Javier Muñoz sobre la hormona GLP-1, más conocida como Ozempic, Semaglutide o Mounjaro. Descubrí qué hay detrás del boom mundial: sus beneficios reales, cómo actúa en el cuerpo y lo que nadie te cuenta.Disclaimer: Este episodio es educativo e informativo. No sustituye la consulta médica.Dale play y compartilo con alguien que también quiera entender de qué se trata todo este boom del GLP-1.Recordá: cuidar tu cuerpo también es honrar el regalo de la vida.

Ecoutez Ça va beaucoup mieux avec Jimmy Mohamed du 18 septembre 2025.Hébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

In this eye-opening episode, Dr. Lindsey Elmore exposes the chaos unfolding in the UK as Mounjaro (weight loss/diabetes medication) prices skyrocket 170% overnight—jumping from £92 to £330 per month. Discover how Eli Lilly's "European price matching" triggered panic buying, crashed pharmacy websites, and left patients spending over £1,000 to stockpile medications. Lindsey examines the real-world impact, even in the U.S.: supply shortages, hoarding behaviors, and the unfair advantage given to those who can afford to bulk-buy versus patients with genuine medical needs. A must-listen for understanding how arbitrary pharmaceutical pricing decisions affect real people's access to life-sustaining medications.Main Topic Introduction00:00-00:30: Discussion focuses on Mounjaro (weight loss/diabetes medication) pricing crisis in the UKThe Price Hike00:37-01:13: Massive 170% price increase starting September 1st, 2025Current price: £92/monthNew price: £330/month (up from planned £122/month)01:25-01:41: Eli Lilly justifies increase as "adjusting prices to match the rest of Europe"Pharmacy Response00:37 & 01:41-02:01: UK's largest online pharmacy "Pharmacy2U" freezes prices, then stops sales entirelyPanic Buying Crisis02:09-02:34: Patients stockpiling medications before price hikes02:22: Pharmacies offering 3, 6, or 9-month bundles02:44-02:59: Real examples: patients buying 7-8 pens, spending over £1,000 in panic purchases04:35: Pharmacy websites crashing from demandSupply Chain Impact02:59-03:24: Hoarding strains supply chains and prevents access for patients who truly need the medication03:24-03:44: Medical experts urge against hoarding injectable medications at homeCore Issues Identified03:51-04:12: Access and fairness concerns - distinguishing between medical necessity vs. cosmetic use05:37-05:57: Drug prices change "for no reason at all" with no patient input06:08-06:27: Need to prioritize patients who medically need medications over those who can afford to stockpileSolutions Proposed04:59-05:27: Work with legislators through existing Inflation Reduction Act framework06:27-06:55: Legislative action needed to control "absurd" arbitrary drug pricing, especially for life-sustaining medicationsEpisode Conclusion07:06-07:14: Show closing: encouraging wise health decisionsBecome a supporter of this podcast: https://www.spreaker.com/podcast/the-lindsey-elmore-show--5952903/support.

I'm leaving for my yearly Disney trip for the T1D conference, and y'all — nothing will humble you more than a three-way dressing-room mirror. I tried on one of those athletic dresses and BAM: back-fat in the mirror I'd never noticed before. Cue the body image vacation panic. But I refused to let bad lighting and spandex steal my trip. In this episode, I tell the whole embarrassing story, exactly how I knocked myself out of that spiral, and why you absolutely cannot put your life on hold until the scale says so.

Sick of trying fad diets that just don't seem to work for you? Find out how to simplify your approach and succeed by learning and applying the principles of weight management.  How to make calories work for you Which proteins are better than others and when to eat protein Preserving lean muscle while losing body fat "Dirty" vs "Clean" diets Including desert and candy during a weight loss journey   APEX RX https://apexrx.net   Jesse Frank https://www.lvrgfit.com jesse.dfrank@gmail.com   Charlie Seltzer https://drseltzerlifestylemedicine.com info@drseltzerweightloss.com

In this episode, Shana Hussin, RDN, shares the replay of her recent webinar on GLP-1 — the hormone behind today's most popular weight loss drugs like Ozempic, Wegovy, and Mounjaro. You'll learn: ✔️ What GLP-1 is and how it works in the body ✔️ Natural ways to increase GLP-1 for fewer cravings, better blood sugar, and fat loss ✔️ Lifestyle habits that decrease GLP-1 and fuel insulin resistance ✔️ The truth about GLP-1 medications: cost, side effects, and sustainability ✔️ How to safely transition off GLP-1 drugs by improving natural GLP-1 and gut health ✔️ The research behind Unimate Yerba Mate and Balance Fiber Matrix — and how they support GLP-1 signaling in the Feel Great System ✨ If you've ever wondered whether you really need expensive GLP-1 medications, or if there's a more sustainable, root-cause solution, this episode is for you. Resources & Links:

Joe's had the ultimate showbiz whirlwind this week, straight from the VMAs to the NTAs! He's giving you the inside scoop on all the standout performances and outfits from the VMAs before joining Kaine for his first ever NTAs. Joe and Kaine reveal their best and worst dressed, Jeremy Clarkson's MOUNJARO revelation (?!) and setting the record straight on those click-bait headlines!

Have you heard about people buying weight loss medications from unregulated sources online? The rise of black market weight loss drugs is putting lives at risk. In this episode, I discuss the concerning trend of people purchasing Retatrutide—a medication still in clinical trials—through illegal channels. Known as the "Godzilla Jab" for its potential power, early studies suggest this drug could help people lose up to 24% of their body weight. I explain what Retatrutide is and how it compares to FDA-approved medications like Ozempic, Wegovy, Zepbound, and Mounjaro. We explore why people take dangerous risks with black market drugs, from social media hype to cost concerns and access issues. Most importantly, I share the serious health and legal risks of buying unregulated medications and provide clear guidelines for safely accessing weight loss treatments through licensed providers. Tune in to learn how to protect yourself and make informed decisions about weight loss medications the safe way.   Episode Highlights: What is Retatrutide The dangers of purchasing unregulated medications online Factors driving people to illegal sources Legal risks of buying unapproved drugs and potential health complications from unregulated substances Safe Medication Practices Understanding that medication works best when combined with healthy eating, physical activity, adequate rest, and emotional support   Connect with Dr. Alicia Shelly: Website | drshellymd.com Facebook | www.facebook.com/drshellymd Instagram | @drshellymd Linked In | www.linkedin.com/in/drshellymd Twitter | @drshellymd   About Dr. Alicia Shelly Dr. Alicia Shelly was raised in Atlanta, GA. She received her Doctorate of Medicine from Case Western Reserve University School of Medicine in Cleveland, OH.  Dr. Shelly has been practicing Primary Care and Obesity medicine since 2014.  In 2017, she became a Diplomat of the American Board of Obesity Medicine. She is the lead physician at the Wellstar Medical Center Douglasville. She started a weekly podcast & Youtube channel entitled Back on Track: Achieving Healthy Weight loss,  where she discusses how to get on track and stay on track with your weight loss journey. She has spoken for numerous local and national organizations, including the Obesity Medicine Association, and the Georgia Chapter of the American Society of Metabolic and Bariatric Surgeons. She has been featured on CNN, Fox 5 News, Bruce St. James Radio show, Upscale magazine, and Shape.com. She was named an honoree of the 2021 Atlanta Business Chronicle's 40 under 40 award. She also is a collaborating author for the, “Made for More: Physician Entrepreneurs who Live Life and Practice Medicine on their own terms''.   Resources: FREE! Discover the 5 Reasons Your Weight-Loss Journey Has Gotten Derailed (And How To Get Back On Track!)

Send us a textAre weight loss drugs like Ozempic, Wegovy, and Mounjaro the miracle breakthrough for obesity and metabolic health—or a dangerous quick fix with hidden risks? In this powerful episode of The Wellness Algorithm with Anshu Bahanda (Wellness Curated), we cut through the hype, celebrity buzz, and TikTok trends to uncover the real science and long-term effects of GLP-1 medications.Joined by leading experts—Dr. Renu Joshi, endocrinologist on the frontlines of obesity and metabolic medicineRebecca Maas, holistic health practitioner and naturopath (author of the upcoming Whole-Body GLP-1 Protocol)Dr. Raj Ragoowansi, renowned plastic surgeon specializing in post-weight-loss transformationsWhether you're considering GLP-1s, already taking them, or simply curious about the wellness conversation reshaping 2025, this episode gives you the science, safety insights, and balanced perspectives you need.✨ Listen now to learn whether weight loss drugs are the future of wellness—or a medical gamble.

Iliza is not inviting anyone on her podcast, so please don't get hacked! Also on the menu, a friend breakup because of Mounjaro and fighting with strangers. See omnystudio.com/listener for privacy information.

Hoy tenemos Consultorio con el Dr. Fernando Pérez Galaz, Médico cirujano especialista en cirugía del aparato digestivo y cirugía bariátrica, y nos va a responder todas las dudas sobre los GLP-1, es decir el Ozempic, Wegovy, Mounjaro y otras marcas más. Hosted on Acast. See acast.com/privacy for more information.

I'm back from my summer break, and today we're talking about what it really means to come out of survival mode and step into a new season of life. When you're just trying to make it through, the world feels blurry. You don't even notice the little things piling up around you. But once you start to shift, it's like everything comes back into focus: the appointments you've been putting off, the house that suddenly needs cleaning, and most importantly, you.In this episode, I'm sharing a summer recap (including an upcoming Disney trip I didn't think would happen), how back-to-school season has me reflecting on my own routines, and why fall is the perfect reminder that change can be beautiful.

In this episode of the Game Changing Health podcast, host Gianna speaks with nurse practitioner Chace Franks, an expert in GLP-1 medications. Chase is a nurse practitioner at IVIM Health which is a telehealth company that recently published exciting new data with semaglutide efficacy rivaling tirzepatide with the IVIM model of care involved in treatment. They discuss the evolution of GLP-1s, their effectiveness in weight management, and the role of telehealth in providing accessible healthcare. Chace shares insights from his experience in prescribing GLP-1s, the importance of supportive healthcare providers, and the challenges of insurance coverage. The conversation also touches on the impact of social media in educating patients and the personal experiences of both speakers with GLP-1s. They emphasize the need for patients to advocate for themselves and seek providers who listen to their concerns.  Follow Chase on TikTok: https://www.tiktok.com/@bourbonrx?_t=ZT-8zeFAlyoBEk&_r=1Follow Chace on Instagram: https://www.instagram.com/bourbonrx1?igsh=MWdrZ3g3N2VzZXU1NQ==Check out IVIM here: https://ivimhealth.sjv.io/QjdoYAKeywords:GLP-1, obesity management, telehealth, weight loss, healthcare providers, insurance coverage, patient education, social media, chronic conditions, health investment ✨ The GLP-1 Circle Membership is opening the doors soon, available for all GLP-1 users, it's your hub for dietitian/personal trainer support on your GLP-1 journey for only $99/month. Get first dibs on membership spots here: Join the waitlist

Começa inquérito em busca das causas do descarrilamento do Elevador da Glória. Psicóloga Li Couto fala sobre o impacto de medicamentos como Ozempic, Mounjaro na nossa saúde mental. A cantora caboverdiana Elida Almeida; comparada à Cesária Évora, fala sobre novo álbum e turnê. Rodrigo Galera de Jesus Madeira e a esposa Ana contam como atravessaram o Brasil a cavalo. Ameba Naegleria fowleri, a ameba 'comedora de cérebro' foi detectada em reservatórios de água potável de duas cidades em Queensland.

In this conversation, Dr. Shawn Tassone discusses the complexities of hormonal health, focusing on the use of GLP-1 medications like Ozempic for weight management. He addresses common misconceptions, the mechanisms of action of these medications, and shares personal experiences and patient outcomes emphasizing the importance of informed decision-making and the need for a supportive healthcare environment to navigate hormonal treatments effectively. Episode Highlights: Ozempic and similar medications are tools for weight management, not without risks. The truth about the black box warning for GLP-1 medications How semaglutide can improve blood sugar levels and reduce cardiovascular risks Why weight loss on these medications should be monitored Why you should avoid obtaining medications from medical spas due to lack of proper oversight How negativity in health discussions often garners more attention than positive messages How individual experiences with weight loss medications can vary significantly Why informed decision-making is crucial when considering hormonal treatments How support from healthcare professionals is essential for successful weight management Resources Dr. Shawn Tassone's Practice | Tassone Advanced Gynecology Dr. Shawn Tassone's Book | The Hormone Balance Bible Dr. Shawn Tassone's Integrative Hormonal Mapping System | Hormonal Archetype Quiz Medical Disclaimer This podcast and website represent the opinions of Dr. Shawn Tassone and his guests. The content here should not be taken as medical advice and is for informational purposes only. Because each person is so unique, please consult your health care professional for any medical questions

Thousands of people who could benefit from weight-loss jab Mounjaro could be missing out due to NHS finding shortfalls.We're joined by project manager Rowanne Miller from the UK's National Robotarium to hear how engineers have developed a flexible robot which could prevent deep sea divers from having to carry out risky underwater inspections.Also in this episode…Domestic abuse charities raise concerns that Sunday's nationwide Emergency Alerts test could reveal hidden phonesThe launch of Hollow Knight: Silksong creates a global gaming frenzy bringing down major gaming storesSky-watchers prepare for Sunday's total lunar eclipse as the Moon turns red over the UKThe image used for this episode shows the tentacle-like underwater robot developed at the UK's National Robotarium which is based at Heriot Watt University's campus in Edinburgh. Credit: Ben Glasgow Hosted on Acast. See acast.com/privacy for more information.

I have high LDL cholesterol and a '0' calcium score.  Why does my doctor insist I take a statin?How much vitamin D should I take?  Which product do you recommend?Some doctors assert omega-3s are proinflammatory.  What say you?Study: Magnesium intake may be beneficial in preventing pancreatic cancerDo you have any products to regrow hair?I have a calcium score, but prefer to avoid Lipitor.

Potato intake and diabetes risk.How much daily leucine is required to regain muscle?

From Facebook groups to celebrity headlines, woen are promoting GLPs (Ozempic, Wegovy, Mounjaro) as magic fix for menopause. Are we mixing hype with science. Are we being sold another expensive quick fix, and what does this mean for women's health.

✨ My GLP-1 Girlie group program is opening again at the end of September for enrollment for an October start date.

Tennis superstar Serena Williams just became the face of a GLP-1 weight loss campaign, and suddenly the conversation around medications like Ozempic, Wegovy, and Mounjaro feels impossible to ignore.             In this episode, I'm sharing the truth about GLP-1s and how they actually work, what I've seen with my own clients who are on them, and the one thing that truly makes weight loss results last.             In this episode, you'll learn:             What GLP-1 medications actually do (and don't do)     Why appetite suppression doesn't solve emotional eating       How muscle loss becomes a hidden risk     The one thing that makes weight loss sustainable long term             This episode is especially for busy, high-achieving women who are curious about GLP-1s but want to know how to use them wisely—or if they even need them at all.            

More than 1.5 million people in the UK now use weight-loss injections like Mounjaro. But as official prices rise by as much as 140%, illegal trade is growing too.Writer: James Tapper and Jessica HaydenProducer: Amalie SortlandHost: Tomini BabsEpisode photography: Alex JonesExecutive Producer: Rebecca MooreTo find out more about The Observer:Subscribe to TheObserver+ on Apple Podcasts for early access and ad-free contentHead to our website observer.co.uk Download the Tortoise app – for a listening experience curated by our journalistsIf you want to get in touch with us directly about a story, or tell us more about the stories you want to hear about contact hello@tortoisemedia.com Hosted on Acast. See acast.com/privacy for more information.

Want to learn more about starting, managing, or transitioning off GLP-1 medications? Join Physique U to attend this Tuesday's live Q&A with GLP-1 expert Justin Silver (and get the replay plus a free custom nutrition plan): bit.ly/wwpu-free-plan--Are GLP-1 medications like Ozempic, Wegovy, and Mounjaro stealing your hard-earned muscle?The short answer is no, but the reality is more nuanced than many realize.Learn why people experience muscle loss while taking weight loss medications. Weight loss medications can be incredible tools when used properly, but like any tool, they work best when combined with fundamental lifestyle strategies that optimize body composition.Support the show

Morse code transcription: vvv vvv Minneapolis school attacker obsessed with idea of killing children, officials say Epping hotel asylum seeker says were in the dark about future US Fed Governor Lisa Cook sues Trump over attempt to fire her European leaders outraged after Russian strikes kill 21 and damage EUs HQ Manchester United Ruben Amorim retains backing of the club MSP locked out of parliament after secret toilet camera claims Jessie J cancels tour dates to undergo further cancer surgery Volunteer Met officer found guilty of child sex offences George Clooney film Jay Kelly praised as midlife crisis masterpiece Price of Mounjaro could be discounted in UK pharmacies

Popular drugs like Ozempic and Mounjaro are back in the headlines this week after former tennis star Serena Williams signed on as an ambassador for a major weight loss company in the US. It comes as Australian health experts warn we still don’t know the long-term consequences of these popular medications, now pushing for all users to also get access to qualified dieticians. In this episode of The Briefing, Natarsha Belling is joined by GP and obesity specialist Dr Terri-Lynne South to unpack these latest developments, and the new health warnings for weight loss drugs here in Australia. Headlines: Matt Wright found guilty, two people questioned by police over Porepunka shootings, and David Hughes in hospital. Follow The Briefing: TikTok: @thebriefingpodInstagram: @thebriefingpodcast YouTube: @LiSTNRnewsroom Facebook: @LiSTNR NewsroomSee omnystudio.com/listener for privacy information.

Morse code transcription: vvv vvv Jessie J cancels tour dates to undergo further cancer surgery European leaders outraged after Russian strikes kill 21 and damage EUs HQ US Fed Governor Lisa Cook sues Trump over attempt to fire her MSP locked out of parliament after secret toilet camera claims Manchester United Ruben Amorim retains backing of the club Epping hotel asylum seeker says were in the dark about future Volunteer Met officer found guilty of child sex offences George Clooney film Jay Kelly praised as midlife crisis masterpiece Price of Mounjaro could be discounted in UK pharmacies Minneapolis school attacker obsessed with idea of killing children, officials say

Morse code transcription: vvv vvv George Clooney film Jay Kelly praised as midlife crisis masterpiece Volunteer Met officer found guilty of child sex offences European leaders outraged after Russian strikes kill 21 and damage EUs HQ Price of Mounjaro could be discounted in UK pharmacies Jessie J cancels tour dates to undergo further cancer surgery MSP locked out of parliament after secret toilet camera claims US Fed Governor Lisa Cook sues Trump over attempt to fire her Epping hotel asylum seeker says were in the dark about future Minneapolis school attacker obsessed with idea of killing children, officials say Manchester United Ruben Amorim retains backing of the club

Morse code transcription: vvv vvv US Fed Governor Lisa Cook sues Trump over attempt to fire her European leaders outraged after Russian strikes kill 21 and damage EUs HQ Epping hotel asylum seeker says were in the dark about future Price of Mounjaro could be discounted in UK pharmacies Manchester United Ruben Amorim retains backing of the club Volunteer Met officer found guilty of child sex offences MSP locked out of parliament after secret toilet camera claims Jessie J cancels tour dates to undergo further cancer surgery George Clooney film Jay Kelly praised as midlife crisis masterpiece Minneapolis school attacker obsessed with idea of killing children, officials say

GLP-1 medications like Ozempic, Wegovy, and Mounjaro are everywhere right now — but are they really the solution for women over 40, or just another shiny trend? In this episode, I share what I've seen firsthand with clients: women who saw zero results, women who lost muscle mass and ended up terrified about regaining weight, and women who learned how to use GLP-1s as a temporary tool — and then get off them faster, with healthier, sustainable results. I'm also talking about something that really disturbs me: the current fad of coaches and influencers hyping these drugs as just another angle to sell themselves. Midlife women deserve better than gimmicks — they deserve real solutions that last. If you've ever wondered whether GLP-1s are a quick fix or a true foundation for change, this one's for you. ⏱️ Timestamps 0:00 – The GLP-1 hype is everywhere 2:05 – What I've seen with clients on meds 4:25 – The problem with weight loss vs. muscle loss 6:50 – How women successfully titrated off GLP-1s 8:45 – Why influencers push GLP-1s as the new marketing angle 10:55 – The “bucket vs. roof” analogy (quick fix vs. foundation) 14:10 – My final take: GLP-1s as a tool, not the foundation Join my new KICKSTART here: https://go.loridoddy.com/metabolic-kickstart-vsl/   When you're ready, here's how I can help you for FREE: (Community + Support) Join my Lori Doddy's Total Wellness community to get research-backed tips, strategies, and free resources to lose weight and manage menopause like  (Lose Fat) Steal my guide with exact 5 Changes I have all clients make in week 1 of working with us, so they lose weight and drop inches even before we put their customized plan in place. Get the guide for free and use it this week!  (Toned Arms) Use these 6 moves to get toned, strong, sexy arms in 15 minutes a day, 2-3 days a week with this guide to Sexy, Strong Arms. (Email List) Sign up to get my tips and strategies plus exclusive content by getting on the LDL Email List!  

Will SpaceX's latest triumph mean Elon Musk will make it to Mars? Why will the price of Mounjaro weightless drugs go up? Benjamin Netanyahu called the IDF's airstrike on Gaza's Nasser Hospital a “tragic misstep" but so far 240 Palestinian journalists have died since the beginning of the conflict.Giles Whittell is joined by the Observer's International Editor, Steve Bloomfield, our Acting National News Editor, Rebecca Myers and reporter, James Tapper, as each try to pitch the top story of the day.Links to the team's Must Reads and recommendations here: Race Across the World‘House of Earth and Blood' by Sarah J. Maas**We want to hear what you think! Email us at: newsmeeting@observer.co.uk Follow us on Social Media: @ObserverUK on X @theobserveruk on Instagram and TikTok@theobserveruk.bsky.social‬ on bluesky Host: Giles WhittellProducer: Amalie SortlandExecutive Producer: Rebecca MooreTo find out more about The Observer:Subscribe to TheObserver+ on Apple Podcasts for early access and ad-free contentHead to our website observer.co.uk Download the Tortoise app – for a listening experience curated by our journalists Hosted on Acast. See acast.com/privacy for more information.

In this episode of the Heart to Heart podcast, Dr. Mike Hart hosts Dr. Chester Sokolowski, a peptide expert and the founder of Thrive Telehealth Clinic, which specializes in hormone replacement therapy (HRT) and peptide treatments for both men and women. Dr. Sokolowski discusses his background, career, and various business ventures focused on human performance and optimization. The conversation delves deep into the benefits and applications of testosterone replacement therapy (TRT), peptides, and other health-related topics. Key points include the implications of TRT, managing estrogen levels, the benefits of combining peptides for muscle growth and recovery, and the groundbreaking potential of GLP-1 agonists like Ozempic and Retatrutide for weight loss and metabolic health. Dr. Sokolowski also touches on the benefits of glutathione, the latest research on peptides such as BPC-157 and TB-500, and the ethical considerations of using these therapies in professional sports. Dr. Chester Sokolowski is a performance optimization expert, telehealth clinician, and leading voice in hormone and peptide therapy. He earned his doctoral training at Florida State University and has dedicated his career to human performance, healthspan, and longevity. Known online as “Dr. Soko”, he shares cutting-edge insights on testosterone therapy, peptides, recovery, and performance through social media and educational content. His work empowers people to look, feel, and perform at their absolute best. Follow him on Instagram: @dr.soko, LinkedIn: Dr. Chester Sokolowski and YouTube: Dr. Soko Links: TRT (Testosterone Replacement Therapy) Ozempic (Semaglutide) DIM (Diindolylmethane) Oxidative stress & disease   Show Notes: (00:00) Introduction to the Heart to Heart Podcast (02:30) Dr. soko's dissertation on binge drinking and muscle growth (06:00) Cold therapy and hypertrophy (08:00) TRT and arimidex discussion (13:35) “Estrogen is not the enemy; it's actually protective for your heart, your brain, your joints.” (14:30) HCG and fertility (20:00) Peptides and GLP-1 drugs (34:30) Minimizing side effects and dosage strategies (35:30) Understanding GLP-1 mechanisms (36:00) Red aide: the unique GLP-1 (39:00) Visceral fat and GLP-1 effectiveness (41:00) GLP-1s and impulse control (46:30) Glutathione: the ultimate antioxidant (50:30) Peptides for skin and hair health (51:00) Growth hormone peptides: which is best? (55:00) BPC-157 and tb-500: healing peptides (01:00:30) TRT, peptides, and sports (01:03:00) Conclusion and contact information   — The Hart2Heart podcast is hosted by family physician Dr. Michael Hart, who is dedicated to  cutting through the noise and uncovering the most effective strategies for optimizing health,  longevity, and peak performance. This podcast dives deep into evidence-based approaches to  hormone balance, peptides, sleep optimization, nutrition, psychedelics, supplements, exercise  protocols, leveraging sunlight light, and de-prescribing pharmaceuticals—using medications only when absolutely necessary.   Beyond health science, we tackle the intersection of public health and politics, exposing how  policy decisions shape our health landscape and what actionable steps people can take to reclaim control over their well-being.   Guests range from out-of-the-box thinking physicians such as Dr. Casey Means (author of "Good Energy") and Dr. Roger Sehult (Medcram lectures) to public health experts such as Dr. Jay Bhattacharya (Director of the National Institutes of Health (NIH) and Dr. Marty Mckary  (Commissioner of the Food and Drug Administration (FDA) and high-profile names such as  Zuby and Mark Sisson (Primal Blueprint and Primal Kitchen).   If you're ready to take control of your health and performance, this is the podcast for you. We cut through the jargon and deliver practical, no-BS advice that you can implement in your daily life, empowering you to make positive changes for your well-being.   Connect on social with Dr. Mike Hart: Instagram: @drmikehart Twitter: @drmikehart Facebook: @drmikehart  

It's nearly impossible to turn on the television or open a magazine without seeing advertisements for the latest weight loss trend: GLP-1 medications, commonly known as Ozempic, Mounjaro, Wegovy, and Zepbound. Approximately 15 million people are estimated to have tried these drugs for weight loss. However, as with any emerging health trend, it's important to consider whether these medications are safe and cost-effective.What are the risks and benefits of these drugs? Is the pharmaceutical industry providing a quick fix for the approximately 42% (or 100 million) U.S. citizens who are obese? Are these medications the only solution to the obesity epidemic, or are lifestyle and dietary changes essential for long-term success? Dr. Nicole Dorotik joins us in this episode to address these questions and more as we explore the latest trends in the pursuit of health and wellness.Special Guest: Dr. Nicole Dorotik Dr. Nicole Dorotik earned her medical degree from the University of Arizona College of Medicine and completed her residency at Long Beach Memorial Hospital in Long Beach, California. She is board-certified in Family Medicine and has over 20 years of clinical experience. Along with her professional accomplishments, Nicole is the proud mom to three great kiddos. Show notes:Weight Comes Back When You Stop Taking Drugs Like Ozempic, Study Finds.https://www.sciencealert.com/weight-comes-back-when-you-stop-taking-drugs-like-ozempic-study-finds#A new era of weight loss: Mental health effects of GLP-1 drugs.https://www.apa.org/monitor/2025/07-08/weight-loss-drugs-mental-healthRx History: The Rise of GLP-1s.https://www.innovativerxstrategies.com/rx-history-glp1s/Unintended consequences: Weight loss drugs are changing the way consumers buy groceries.https://www.post-gazette.com/business/healthcare-business/2025/08/17/glp1-ozempic-grocery-store-food-price-weightloss/stories/202508070069.

Schweizerinnen und Schweizer sind in der Altersvorsorge für die Umsetzung neuer Lösungsansätze bereit. Das zeigt eine neue Umfrage des Beratungsunternehmens Deloitte Schweiz. Eine generelle Erhöhung oder ein Einfrieren des Rentenalters wird darin aber klar abgelehnt. Weitere Themen: Abnehmspritzen wie Ozempic, Wegovy oder Mounjaro erleben aktuell einen regelrechten Hype. Auch in der Schweiz. Doch die grosse Nachfrage birgt Gefahren: etwa durch das vermehrte Aufkommen von Nachahmer-Produkten. Seit zwei Wochen patrouillieren in der US-Hauptstadt Washington D.C. rund 2000 Angehörige der Nationalgarde. Offiziell will Donald Trump damit die Kriminalität bekämpfen. Eine deutliche Mehrheit der Bevölkerung glaubt aber, es gehe um Einschüchterung.

Resources for the Community:___________________________________________________________________https://linktr.ee/theplussidezpodcast Ro - Telehealth for GLP1 weight management https://ro.co/weight-loss/?utm_source=plussidez&utm_medium=partnership&utm_campaign=comms_yt&utm_content=45497&utm_term=55Find Your US Representatives https://www.usa.gov/elected-officials ______________________________________________________________________Today is a Plus SideZ Rewind! Two years ago, we sat down with the one and only Rosie O'Donnell at the dawn of our movement for affordable access to GLP-1 medications & ending the stigma around treating obesity as a disease. Now, as we stand well into season five with thousands of new subscribers, so it's time for a little time-travel! We're bringing you a “Rewind” of that pivotal conversation to let our new listeners hear where it all began and let our longtime supporters see just how far we've come.In this flashback, we revisit that summer of 2023 when the Mounjaro $25 Savings Card Coupon was ending and people were flocking to compound GLP-1 which still had a lot of question marks surrounding it. And the shortage of all GLP-1s was growing. There was no Zepbound or cash pay price or branded vials. It was $1400-1000 a month go get access to branded GLP-1s. With more voices in the conversation today, we're measuring our progress from that. Oh how far we've come! We can now get branded GLP-1 for under $500. That's a ton of movement in a short time. But let's get it lower! Keep the faith. Let's get loud AND change things! ______________________________________________________________________⭐️Mounjaro Stanley⭐️griffintumblerco.Etsy.comUse code PODCAST10 for $ OFF______________________________________________________________________Join this channel to get access to perks:   / @theplussidez______________________________________________________________________#Mounjaro #MounjaroJourney #Ozempic #Semaglutide #tirzepatide  #GLP1 #Obesity #zepbound #wegovy Send us Fan Mail!Support the showKim Carlos, Executive Producer TikTok https://www.tiktok.com/@dmfkim?is_from_webapp=1&sender_device=pc Instagram https://www.instagram.com/dmfkimonmounjaro?igsh=aDF6dnlmbHBoYmJn&utm_source=qr Kat Carter, Associate Producer TikTok https://www.tiktok.com/@katcarter7?is_from_webapp=1&sender_device=pc Instagram https://www.instagram.com/mrskatcarter?utm_source=ig_web_button_share_sheet&igsh=ZDNlZDc0MzIxNw==

✨ My GLP-1 Girlie group program is opening again at the end of September for enrollment for an October start date.

Even though GLP-1 drugs have helped nearly 20 million people shed weight across the world since 2021, Indians had to wait until 2025 to get in on the action legally.To be fair, the country wasn't entirely in the dark. Semaglutide—the molecule behind pharma giant Novo Nordisk's blockbuster drugs Ozempic and Wegovy—was already available for diabetes treatment. But this March, Eli Lilly's Mounjaro (which uses a different molecule, tirzepatide) entered the market. In July, Wegovy arrived. And suddenly, India went from “we know GLP-1” to “we want the skinny shot”.Since then, the GLP-1 market in India—across diabetes and weight loss—has grown from Rs 531 crore to Rs 628 crore. And now, depending on the vantage point, things are about to get much bigger. And much cheaper.And naturally, pretty much every major Pharma major wants in on the action. Tune in. Do you work in IT? Take our surveyWant to join The Ken's team? Fill this form. 

Welcome back to The Midlife Mentors! We're shaking things up with a brand new format we're calling Hot Topics.Each month we'll take a look at some of the stories making headlines that we think matter most to us in midlife - whether that's health, money, culture, or just things that get us talking.This week we're diving into the shocking Mounjaro price hike and what it means for people trying to look after their health, the growing Gen X pension gap, and the controversy around L'Oréal hiring an OnlyFans model for a major campaign.Plenty of food for thought, a bit of debate, and of course, our take on what it all means for midlifers like you. So let's get into this month's Hot Topics.Ibiza Retreat: https://themidlifementors.com/retreats/The Midlife Male Handbook available now:AmazonWaterstonesWH Smith Please remember, if you find the show helpful or it makes you laugh, motivates and inspires you - please do like, share and rate us. We don't run ads on the podcast or for the show, because we want to keep it as enjoyable for you to listen as possible. So if you can help us spread the word, we'd be incredibly grateful.For more information about The Midlife Mentors, click the below link:https://linktr.ee/themidlifementors.comTik Tok: @themidlifementorsIG: @midlifementors

In the past couple years, demand has gone wild for drugs like Ozempic – and its cousins, Zepbound, Wegovy, and Mounjaro. For people who had never been able to lose weight before, suddenly the numbers on the scale were plummeting. And everybody wanted to get their hands on them. Now, in most industries, if a product goes viral like this, it's a golden ticket. And thanks to government-granted monopolies designed to encourage innovation, the big drug companies behind these blockbuster injections are currently the only ones allowed to make them.In theory, anyway. But, what if that explosive demand backfired, opening the door to legal knock-offs? You've maybe seen them - copycats advertised as the same thing as Ozempic. So, what's the difference? And just how legal are they? On today's show - a drug that's changing people's lives is also challenging the traditional way we buy and sell medicine.This episode was hosted by Sydney Lupkin and Jeff Guo. It was produced by James Sneed. It was edited by Marianne McCune, fact-checked by Sierra Juarez, and engineered by Gilly Moon and Debbie Daughtry. Alex Goldmark is Planet Money's executive producer.Listen free at these links: Apple Podcasts, Spotify, the NPR app or anywhere you get podcasts.Find more Planet Money: Facebook / Instagram / TikTok / Our weekly Newsletter.Help support Planet Money and hear our bonus episodes by subscribing to Planet Money+ in Apple Podcasts or at plus.npr.org/planetmoney.Music: Source Audio - “Subtly Silly Thug,” “Got The Moves,” and “Vive le Punk”Learn more about sponsor message choices: podcastchoices.com/adchoicesNPR Privacy Policy

Andrea dives into a topic she's been closely following for a long time: GLP-1 medications like Ozempic, Wegovy, and Mounjaro. As a personal trainer and nutrition coach, she breaks down what GLP-1s are, how they work, their benefits and side effects, and most importantly, whether they serve as a catalyst or a crutch in someone's health journey. Drawing from real-life scenarios, client experiences, and extensive research, Andrea brings a clear, thoughtful perspective to a complex and often controversial subject. This episode offers practical insight for anyone considering GLP-1s or supporting someone who is.Make Fit Simple Podcast is sponsored by KION. Go to Getkion.com/simple for 20% OFFMake it Simple is sponsored by Goodr SunglassesUse code SIMPLE at check out for FREE SHIPPINGhttp://goodr.com/MAKEITSIMPLEStudies: https://diabetesjournals.org/care/article/48/2/292/157724/Efficacy-of-GLP-1-Receptor-Agonists-on-Weight-Loss https://www.amjmed.com/article/S0002-9343%2825%2900059-2/fulltext Improved Dementia https://pmc.ncbi.nlm.nih.gov/articles/PMC8864443/   Decreasing Cardiovascular Disease https://pmc.ncbi.nlm.nih.gov/articles/PMC10739421/ Gastrointestinal Issues https://pmc.ncbi.nlm.nih.gov/articles/PMC10557026/-  Addictions https://www.nature.com/articles/s41591-024-03412-w   PODCASTS on GLP-1 https://podcasts.apple.com/us/podcast/just-ingredients/id1557557205?i=1000679752979 https://podcasts.apple.com/us/podcast/the-dr-tyna-show/id1577258582?i=1000709323014 https://podcasts.apple.com/us/podcast/the-dr-tyna-show/id1577258582?i=1000681609168  Follow the Make Fit Simple Podcast@MakeFitSimplePodcastHave a suggestion for a topic click HEREHave a suggestion for a guest click HERENEW! Leave a question for Andrea HERE on SpeakPipe! Follow Andrea on Instagram@deliciouslyfitnhealthy@dfh.training.picsTraining & Coachinghttps://www.deliciouslyfitnhealthy.com/linksVisit Andrea's Websitewww.deliciouslyfitnhealthy.comProduced by Light On Creative Productions

In this episode, we look at the new "wonder drugs" that are wreaking havoc on people's lives.Show NotesAlcor Life Extension Foundation: https://en.wikipedia.org/wiki/Alcor_Life_Extension_FoundationFred and Linda Chamberlain https://en.wikipedia.org/wiki/Fred_and_Linda_Chamberlain Mike Darwin https://en.wikipedia.org/wiki/Mike_DarwinThe Great Ozempic Scam https://www.theburningplatform.com/2024/09/12/the-great-ozempic-scam Semaglutide https://en.wikipedia.org/wiki/Semaglutide Drug trial snapshot:  https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trial-snapshot-ozempic Can Ozempic Kill You? https://www.motleyrice.com/diabetes-lawsuits/ozempic/safe-for-weight-loss/deathsTirzepatide, or Mounjaro https://en.wikipedia.org/wiki/Tirzepatide Tirzepatide is a peptide The Cardiovascular Effect of Tirzepatide: A Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide Dual Agonist https://pubmed.ncbi.nlm.nih.gov/37800107/ This Is What Happens When You Inject Yourself With Reptile Venom Peptides Marketed as FDA-Approved Weight Loss Drugs https://discernreport.com/this-is-what-happens-when-you-inject-yourself-with-reptile-venom-peptides-marketed-as-fda-approved-weight-loss-drugs/

GLP-1 medications like Ozempic, Wegovy, and Mounjaro have become household names, celebrated as breakthrough treatments for weight loss and obesity. But while headlines showcase dramatic before-and-after photos and promises of rapid transformation, when we step beyond the marketing, a more nuanced reality comes to light.In this candid conversation, Dr. Mark Cucuzzella, a family medicine physician, and Dr. Tro Kalayjian, board-certified in internal and obesity medicine, draw on decades of clinical experience to examine where GLP-1s truly shine, where they fall short, and why the foundation for lasting health can't come from a prescription alone.They make the case for integrating GLP-1s into a comprehensive care plan, one that addresses nutrition, movement, sleep, and stress. Without these pillars, patients face higher risks of side effects, reduced long-term benefits, and the all-too-common rebound weight gain.In this interview, you'll learn:Which patients benefit most from GLP-1 therapy (and which may not)How “medication stewardship” ensures safe, responsible useWhy starting at the lowest effective dose and tapering mattersHow lifestyle-first programs can match or exceed drug results at a fraction of the costDrs. Cucuzzella and Kalayjian remind us that true success lies in restoring metabolic health and building habits that last long after the injection ends. GLP-1 medications can be powerful allies, but they're not a silver bullet. Without a foundation of nutrition, movement, sleep, and stress management, they risk becoming just another short-term fix.Expert Featured:Dr. Mark CucuzzellaWebsite: https://www.drmarksdesk.com/Dr. Tro KalayjianWebsite: https://toward.health/IG: https://www.instagram.com/doctortro/X: https://x.com/DoctorTroResources Mentioned:TOWARD: a metabolic intervention that improves addiction and binge eating symptomshttps://doi.org/10.3389/fpsyt.2025.1612551CMEs Mentioned:Managing Major Mental Illness with Dietary Change: The New Science of Hopehttps://www.mycme.com/courses/managing-major-mental-illness-with-dietary-change-9616Brain Energy: The Metabolic Theory of Mental Illnesshttps://www.mycme.com/courses/brain-energy-the-metabolic-theory-of-mental-illness-9615Follow our channel for more information and education from Bret Scher, MD, FACC, including interviews with leading experts in Metabolic Psychiatry.Learn more about metabolic psychiatry and find helpful resources at https://metabolicmind.org/About us:Metabolic Mind is a non-profit initiative of Baszucki Group working to transform the study and treatment of mental disorders by exploring the connection between metabolism and brain health. We leverage the science of metabolic psychiatry and personal stories to offer education,...

Episode 2685 - Vinnie Tortorich and Anna Vocino discuss the abuse of weight loss drugs, understanding sugar in your body, and more. https://vinnietortorich.com/2025/08/understanding-sugar-episode-2685 PLEASE SUPPORT OUR SPONSORS YOU CAN WATCH ALL THE PODCAST EPISODES ON YOUTUBE - Abusing Weight Loss Drugs Vinnie has been travelling lately on a long road trip. (2:00) They discuss how they pack snacks for a road trip. There is some concerning behavior surrounding the use of Mounjaro. (9:30) Rather than eating healthy, people still want to eat poorly, but ramp up the usage of the drug. There is an emotional component behind overeating. (12:30) Understanding Sugar Why is sugar so bad? (21:45) They discuss macros and how much sugar your body needs at any one time. (23:00) If you don't load your body with carbs, then your body will burn fat, which is a good thing. The amount of sugar you need varies depending on your activity. (25:00) For example, a boxer in the ring will burn through sugar very fast. However, there are many activities where your body can produce what it needs with gluconeogenesis. Any extra sugar is stored as fat, or long-chain triglycerides. According to a recent interview Vinnie had with Dr. Tro, it's not uncommon for people to be on 19 medications. (29:00) The national average is 8 drugs. Vinnie explains complex carbs and the myth that claims they are better for you. (33:00) A glycogen load is bad because it causes your body to continually release insulin. Grains are starches, and starches are sugar. However, don't become carb-phobic. That's where Vinnie's rule of Life Into Living (LIL) comes in. (37:00) If you are in Italy, have the gelato: meaning on a truly special, limited occasion, enjoy yourself. Just don't let LIL become frequent or rampant. They chat about travelling and Chamonix. (40:00) Eat Happy Kitchen is for everyone, and several of the sauces are vegan. (46:30) Anna's sauces are in several stores. Go to her website and use the store locator to find the store closest to you. Keep listening because Anna will be sharing new wings recipes for Football season! (54:00) Vinnie explains how you'll be able to join the NSNG® VIP group when it reopens soon! If you are interested in the NSNG® VIP group, register here! More News If you are interested in the NSNG® VIP group, register here! Don't forget to check out Serena Scott Thomas on Days of Our Lives on the Peacock channel.  “Dirty Keto” is available on Amazon! You can purchase or rent it . Make sure you watch, rate, and review it! Eat Happy Italian, Anna's next cookbook, is available!  You can go to You can order it from . Anna's recipes are in her cookbooks, website, and Substack–they will spice up your day! There's a new NSNG® Foods promo code you can use! The promo code ONLY works on the NSNG® Foods website, NOT on Amazon. https://nsngfoods.com/   PURCHASE  DIRTY KETO (2024) The documentary launched in August 2024! Order it TODAY! This is Vinnie's fourth documentary in just over five years. Visit my new Documentaries HQ to find my films everywhere: Then, please share my fact-based, health-focused documentary series with your friends and family. Additionally, the more views, the better it ranks, so please watch it again with a new friend! REVIEWS: Please submit your REVIEW after you watch my films. Your positive REVIEW does matter! PURCHASE BEYOND IMPOSSIBLE (2022) Visit my new Documentaries HQ to find my films everywhere: REVIEWS: Please submit your REVIEW after you watch my films. Your positive REVIEW does matter! FAT: A DOCUMENTARY 2 (2021) Visit my new Documentaries HQ to find my films everywhere: FAT: A DOCUMENTARY (2019) Visit my new Documentaries HQ to find my films everywhere:

✨ My GLP-1 Girlie group program is opening again at the end of September for enrollment for an October start date.

GLP-1 medications such as Ozempic and Mounjaro are transforming lives, yet there is another side to the story that rarely appears on social media. In this episode, Chalene Johnson examines how influencer culture, black-market “research chemicals,” and questionable compounding pharmacies are profiting from the growing demand. She explores the risks of rapid weight loss that can quietly diminish muscle mass and the rise of MLM-style promotions aimed at midlife women. Listeners will gain insight into the realities behind the trend and learn ways to avoid potentially dangerous shortcuts. Watch this episode on YouTube this Sunday!!  https://www.youtube.com/@chalenejohnson/videos  

 It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: cancer reserach may lead to T1D treatment, GLP-1 oral pill moves forward, Tandem pharmacy moves, Medtronic-Abbott sensor unveield, parents of kids with T1D see income drop, Mannkind submits Afrezza for pediatrics, diabetes scholarships and more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom   Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links:   Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX Cornell researchers have developed an implant system that can treat type 1 diabetes by supplying extra oxygen to densely packed insulin-secreting cells, without the need for immunosuppression. The system could also potentially provide long-term treatment for a range of chronic diseases. This lab has produced previous implantable devices that have proved effective in controlling blood sugar in diabetic mice, but they can only last so long. "It's the proof of concept. We really proved that oxygenation is important, and oxygenation will support high cell-density capsules," Tempelman said. "The capsules are immune protective and last for a long time without having some kind of fouling of the membrane. The body never likes it when you put a foreign substance in. So that's the engineering in the Ma Lab, to look for materials and coatings for the materials that are immune protective, but also don't invoke excess response from the body because of the material." The next step will be to implant the system in a pig model, and also test it with human stem cells. The researchers are interested in eventually trying to use the system for implanting different cell types in humans for long-term treatment of chronic diseases, according to Tempelman, who is CEO of Persista Bio Inc., a new startup she founded with Ma and Flanders that is licensing these technologies. https://medicalxpress.com/news/2025-08-implant-diabetes-oxygenating-insulin-cells.html XX Mayo Clinic cancer research may be big news for T1D. After identifying a sugar molecule that cancer cells use on their surfaces to hide from the immune system, the researchers have found the same molecule may eventually help in the treatment of type 1. Cancer cells use a variety of methods to evade immune response, including coating themselves in a sugar molecule known as sialic acid. The researchers found in a preclinical model of type 1 diabetes that it's possible to dress up beta cells with the same sugar molecule, enabling the immune system to tolerate the cells. The findings show that it's possible to engineer beta cells that do not prompt an immune response   In the preclinical models, the team found that the engineered cells were 90% effective in preventing the development of type 1 diabetes. The beta cells that are typically destroyed by the immune system in type 1 diabetes were preserved.     https://newsnetwork.mayoclinic.org/discussion/mayo-clinic-researchers-find-sugar-coating-cells-can-protect-those-typically-destroyed-in-type-1-diabetes/ XX A daily pill may be as effective in lowering blood sugar and aiding weight loss in people with Type 2 diabetes as the popular injectable drugs Mounjaro and Ozempic, according to results of a clinical trial announced by Eli Lilly on Thursday morning.   The drug, orforglipron, is a GLP-1, a class of drugs that have become blockbusters because of their weight-loss effects. But the GLP-1s on the market now are expensive, must be kept refrigerated and must be injected. A pill that produces similar results has the potential to become far more widely used, though it is also expected to be expensive.   Lilly said it would seek approval from the Food and Drug Administration later this year to market orforglipron for obesity and early in 2026 for diabetes. https://www.nytimes.com/2025/04/17/health/pill-glp-1-eli-lilly.html XX Use of diabetes technology has dramatically increased and glycemic control has improved among people with type 1 diabetes (T1D) in the US over the past 15 years, but at the same time, overall achievement of an A1c level < 7% remains low and socioeconomic and racial disparities have widened. These findings came from an analysis of national electronic health records of nearly 200,000 children and adults with T1D by Michael Fang, PhD, of the Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, and colleagues. The study was published online on August 11, 2025, in JAMA Network Open. Use of continuous glucose monitors (CGMs) increased substantially from 2009-2011 to 2021-2023, from less than 5% in both children and adults to more than 80% and over half, respectively. While A1c levels did drop over the 15 years, just 1 in 5 children and slightly over a quarter of adults achieved a level < 7%. The average A1c level stayed above 8%, with ethnic minorities and low-income patients seeing the smallest gains.       https://www.medscape.com/viewarticle/diabetes-tech-use-rise-a1c-reductions-still-lag-2025a1000lc9 XX Inflammation may predict how well people with diabetes respond to depression treatment, and the effects differ dramatically between type 1 and type 2 diabetes. Diabetes and depression often appear together. Indeed, depression is more than three times more prevalent in people with type 1 diabetes (T1D) and nearly twice as prevalent in people with type 2 diabetes (T2D). When they appear together, treatment for depression can vary widely. In a new study, researchers from the German Diabetes Center (DDZ), the Research Institute of the Diabetes Academy Mergentheim (FIDAM), and the German Center for Diabetes Research (DZD) investigated how inflammation in the body relates to improvement in depression symptoms in people with T1D and T2D. The researchers combined data from three previous German randomized clinical trials that aimed to reduce elevated depressive symptoms and diabetes distress in people with type 1 or type 2 diabetes. Diabetes distress is characterized by feelings of overwhelm, frustration, guilt and worry about diabetes management and its potential complications. A total of 332 participants with T1D and 189 with T2D who had completed both a baseline and 12-month follow-up examination were included in the present study. Measures included depression using the Center for Epidemiological Studies Depression scale (CES-D), blood tests for 76 inflammatory biomarkers, and symptoms broken down into cognitive-affective (e.g., feeling hopeless), somatic (e.g., poor sleep, fatigue), and anhedonia (loss of pleasure) clusters.   After adjusting for factors like age, body mass index (BMI), diabetes duration, cholesterol, and co-existing illnesses, the researchers found that in patients with T1D, higher baseline inflammation was linked to smaller improvements in depression. Inflammation seemed to be more connected to physical/somatic symptoms in T1D patients. In those with T2D, higher baseline inflammation was linked to greater improvements in depression. For these patients, the effect was strongest for cognitive-affective and anhedonia – so, emotional and motivational – symptoms.   The researchers weren't sure what caused the difference between T1D and T2D, but they suggest it might be due to the different forms of immune activation seen in each condition. That is, autoimmune processes in type 1 and metabolic inflammation in type 2. https://newatlas.com/health-wellbeing/inflammation-diabetes-depression-treatment/ XX Parents of children diagnosed with type 1 diabetes suffer an income drop in the years following the diagnosis. The impact is more pronounced in mothers, especially mothers of children diagnosed in preschool years. And these findings come from a European study.. not the US. Previous research has shown that parents of children with type 1 diabetes are at increased risk of stress-related symptoms and may need to reduce their working hours. "In our study, we observed reduced parental work-related incomes in the years following the child's type 1 diabetes diagnosis. The drop was larger in mothers than in fathers. Since mothers earned significantly less than fathers in absolute terms, even before the child fell ill, the relative drop in mothers was 6.6% the year following diagnosis compared to 1.5% in fathers. We further note the greatest impact on work-related incomes in mothers of children diagnosed at preschool age," says Beatrice Kennedy, physician at the Endocrine and Diabetes unit at Uppsala University Hospital and Associate Professor of Medical Epidemiology at Uppsala University, who led the study. This is a huge study, builds on data from national population and health registers and the Swedish Child Diabetes Register (Swediabkids). The study includes the parents of more than 13,000 children diagnosed with type 1 diabetes in Sweden in 1993−2014, as well as more than half a million parents in the general population who have children not diagnosed with diabetes.   The researchers observed that the maternal pension-qualifying incomes (a composite outcome including work-related income and societal benefits) initially increased after the child's diagnosis. This was attributable to mothers applying for the parental care allowance from the Swedish Social Insurance Agency. The parental care allowance was intended to compensate for disease-related loss of work-related income and contribute toward disease-specific costs.   When the research team investigated long-term effects in mothers, they found that the pension-qualifying incomes gradually decreased after eight years, and had not recovered by the end of follow-up − 17 years after the children were diagnosed. https://www.news-medical.net/news/20250811/Mothers-face-greater-financial-impact-following-childe28099s-type-1-diabetes-diagnosis.aspx XX The U.S. Department of Justice has reached a settlement with Metro Nashville Public Schools after allegations that the district violated the Americans with Disabilities Act.   The parents of a student at the Ross Early Learning Center requested that the school monitor their child's glucose monitor. Investigators found the school refused to do so, despite the child's Type 1 Diabetes diagnosis.   As part of the settlement, MNPS agreed to change its policies to allow the use of these devices, ensure trained staff can monitor them throughout the entire school day and at school activities, and improve communication with parents. https://www.wsmv.com/2025/08/12/metro-nashville-public-schools-settles-allegations-it-discriminated-against-students-with-diabetes/ XX Modular Medical has unveiled Pivot, its next-generation insulin patch pump technology aimed at simplifying diabetes care. The company announced its new pump for “almost-pumpers” at the Association of Diabetes Care & Education Specialists (“ADCES”) Conference in Phoenix, Arizona this weekend. It aims for Pivot to target adults with a user-friendly, affordable design.   Modular Medical's current pump, the MODD1, won FDA clearance nearly a year ago. It features new microfluidics technology to allow for the low-cost pumping of insulin. The system has a reservoir size of 300 units/3mL. Users can monitor the pump activity with their cell phone and do not require an external controller. The pump uses a provided, single-use, disposable battery.   The company announced recently that it validated its insulin pump cartridge line for human-use production in the U.S. Days later, it reported the first human use of the MODD1 pump.   Now, it has taken the next steps with the debut of a next-gen pump, set for FDA submission in October.   Modular Medical also gamifies diabetes care The company also said ADCES is the place where it will showcase the first playable level of its new Pivot pump gamified trainin module. Level Ex, a developer of medical games, develops the module.   Modular Medical said gamification offers a way to make medical training more effective and efficient while improving information retention. Given the complexity in pump uptake, the company hopes to provide an easy way to bring its technology to clinicians and patients.   The company expects to have training modules available at the same time as the pump's planned launch in 2026.   “Level One is free because diabetes mastery shouldn't come with a price tag,” Sam Glassenberg, CEO of Level Ex, said. “Modular Medical is breaking barriers too – bringing pump therapy to more people through smart, accessible design. Together, we intend to make diabetes management simpler and more inclusive.   “People learn best through play – and we believe they want to learn about insulin pumps the same way. In Level One, players aren't just mastering diabetes management through gameplay – they're asking to ‘play' with pumps: to explore how they work, understand their benefits, and build confidence before using them in real life. Our partnership with Modular Medical helps make that possible.” https://www.drugdeliverybusiness.com/modular-medical-unveils-next-gen-insulin-pump/ XX On Tuesday, 12 August 2025, Tandem Diabetes Care (NASDAQ:TNDM) presented at the Canaccord Genuity's 45th Annual Growth Conference, outlining strategic shifts and market focus. The company highlighted its plans for commercial transformation in the U.S. and expansion in international markets, alongside addressing competitive challenges and regulatory impacts. While optimistic about growth in Outside the U.S. (OUS) markets, Tandem is navigating a more competitive landscape domestically. We have entered into the pharmacy channel with Mobi only. And so as Mobi's been building up volume, we're getting experience and we're really learning and understanding what pharmacy offers to us. And the proof points have proved out the thesis I said earlier, which is it can really reduce that barrier for patients, is the out of pocket cost. And so we've decided to accelerate our strategy and where we were starting just with Mobi, we are now moving t slim supplies into the pharmacy channel, and that will kick into gear in the fourth quarter. So as people are looking at the cadence of sales for the remainder of the year with this reframing, many folks are seeing what looks like a a might be an outsized fourth quarter and and having trouble understanding those dynamics. We'll be adding the tSIM supplies to those contracts. We also have more coverage. We will have it in the coming weeks effective this year, so we will be increasing that 30% rate before the end of the year. And then, obviously, everyone's in the same cycle right now already negotiating and discussing their 2026 coverage. And so 30% is the floor.   We do expect to continue to grow that coverage in the coming years, and ultimately have a much broader access. Absolutely. It's an exciting technology that allows for us to have an infusion set that extends the wear time from three days to up to seven days. So we're able to use that as part of an independent infusion set, which would then be used with the t slim and with the mobi pump today. But we're also using that same technology as part of the site that's used for mobi when you use it with a tubeless cartridge. So next year, we will launch Mobi in a patch configuration.   It uses the same pump that's available today, but by using a modified cartridge, you're able to wear it as a patch pump. So one of the things we announced on the call is that we're using this extended wear technology as part of that site. So what it allows you to do is to change the portion that you wear in your skin separate from the timing of when you change the insulin cartridge. So it allows for that extended wear time, reduction of burden to the patient, which is especially important for higher volume insulin users as we expand into type two. So from here, we will launch the extended wear site next year along with we'll do a separate regulatory filing for the cartridge portion for Mobi that includes this extended wear technology as a predicate device. So that's another filing that we'll need to do, but we have the clearance today for the independent infusion set, but we'll file another five ten k for use of the extended wear technology as part of the tubeless Mobi feature. https://za.investing.com/news/transcripts/tandem-diabetes-at-canaccord-conference-strategic-shifts-and-market-focus-93CH-3834464 XX MannKind today announced a significant regulatory submission and a large financing agreement with Blackstone. The company submitted its lead inhaled insulin product for expanded FDA approval and secured $500 million in funding, it said.   First, the Danbury, Connecticut-based company announced that it submitted a supplemental Biologics License Application (sBLA) for Afrezza, its inhaled insulin product, in the pediatric population.   MannKind Director of Medical and Scientific Engagement Joanne Rinker, MS, RDN, BC-ADM, CDCES, LDN, FADCES, told Drug Delivery Business News at ADA 2025 that a submission was on the way for children and adolescents aged 4-17 years old. Further data shared at ADA found Afrezza both safe and effective in that age range.   Afrezza is a fast-acting insulin formulation delivered through an inhaler device. MannKind engineered the mechanical inhaler device to slowly bring powder into the lung. A small compartment opens for the insertion of the insulin cartridge, then the user closes it. The only other component is a mouthpiece for the sake of cleanliness. Then, the inhalation takes just two seconds. It requires no electronics or extra components.   The company expects a review acceptance decision early in the fourth quarter of 2025.   “The submission of our supplemental Biologics License Application (sBLA) for Afrezza in pediatric patients is a meaningful milestone for MannKind and people living with diabetes,” said Michael Castagna, CEO of MannKind Corporation.   Additional funding provides a significant boost for MannKind MannKind also announced a strategic financing agreement with funds managed by Blackstone worth up to $500 million. The financing provides MannKind with non-dilutive capital to advance its short- and long-term growth strategies.   This senior secured credit facility includes a $75 million initial term loan funded at closing. It then has a $125 million delayed draw term loan available for the next 24 months. Finally, it features an additional $300 million uncommitted delayed draw term loan available at the mutual consent of MannKind and Blackstone.   The facility bears interest at a calculated SOFR variable rate plus 4.75% and matures in August 2030.   “This strategic financing significantly increases our operating flexibility and provides us substantial access to non-dilutive capital on favorable terms, complementing our strong cash position,” said Castagna. “The funding will support the expansion of our commercial team in preparation for the anticipated launch of the pediatric indication for Afrezza, if approved, continued pipeline advancement, potential business development opportunities, and general corporate purposes. Partnering with the Blackstone team on this transaction positions us to accelerate our next phase of growth and innovation.” https://www.drugdeliverybusiness.com/mannkind-fda-submission-pediatrics-500m-blackstone/ XX   Medtronic MiniMed Abbott Instinct Sensor [Image from Medtronic Diabetes on LinkedIn] The Medtronic Diabetes business today took to social media to share an early preview of a new integrated Abbott sensor for its insulin delivery systems. Medtronic Diabetes — soon to be MiniMed after its planned separation from the medtech giant – said in the post that the new sensor specifically designed for its own systems is called “Instinct.”   “Get a sneak peek at what's coming next: the Instinct sensor,” the business unit's account wrote. “Made by Abbott, the Instinct sensor is designed exclusively for MiniMed systems. We'll share more details about the Instinct sensor when it's commercially available.”   The sensor, built on the Abbott FreeStyle Libre platform, reflects “the power of the partnership,” Abbott EVP, Diabetes Care, Chris Scoggins, told Drug Delivery Business News earlier this year.   Medtronic and Abbott — two of the largest diabetes tech companies in the world — announced a year ago that they entered into a global partnership pairing Abbott continuous glucose monitors (CGMs) with Medtronic insulin delivery systems.   The partnership aims to collaborate on a system based on Abbott's FreeStyle Libre CGMs with Medtronic's automated insulin delivery technology (the latest generation being the MiniMed 780G) and smart insulin pen systems, such as the InPen system.   Read more about Medtronic, Abbott and the rest of the diabetes tech industry in our free Diabetes Technology Special Report. Medtronic's systems previously used its own CGMs, such as the Guardian 4 and the Simplera platform, and the company intends to continue using those systems as part of a comprehensive CGM portfolio. Under the companies' agreement, the systems would be sold exclusively by Medtronic — including the Abbott CGM.   The companies brought the partnership a step further in April when Medtronic announced the submission of an interoperable pump with the Abbott sensor technology to the FDA. They plan to share more details following the expected FDA clearance, which remains pending.   Management also recently emphasized the multi-year nature of the partnership, meaning Medtronic could pair current and future pumps with other Abbott sensors in the future. That could hint at integration with the company's future dual glucose-ketone monitor, as a number of pump makers have already announced collaborations to pair their systems with the sensor once it hits the market. https://www.drugdeliverybusiness.com/medtronic-diabetes-previews-abbott-sensor-minimed/ XX Governor Glenn Youngkin joined Civica officials at the company's Petersburg manufacturing facility to announce a $3 million grant from the Commonwealth of Virginia to accelerate Civica's efforts to develop and produce affordable insulin for Americans living with diabetes.   CivicaRx Logo   "We are proud to partner with Civica in their mission to make essential medicines more accessible," said Governor Youngkin. "This investment reflects our belief in the power of public-private collaboration to improve lives and strengthen communities."   These funds will support the production of insulin aspart, a rapid-acting human insulin analog used to regulate blood sugar in adults and children with diabetes. Civica plans to produce both rapid- and long-acting insulins at its state-of-the-art manufacturing facility in Petersburg, Va., where the company now employs more than 200 skilled workers.1 Over 8 million people living with diabetes need rapid-acting and/or long-acting insulin.   The Governor also announced that he had officially proclaimed August 7 – 14 2025 'Life Sciences Week' demonstrating the Commonwealth's commitment to "accelerating the advancement of the life sciences through public-private partnerships, STEM education, workforce development, and sustained investment in research and development."   "We are grateful for the Commonwealth's support," said Ned McCoy, Civica's President and CEO. "This funding will help us move closer toward our goal of ensuring that no one has to choose between insulin and other basic needs."   Civica and Virginia officials were joined by Lynn Starr, Chief Global Advocacy Officer of Breakthrough T1D, the leading global type 1 diabetes research and advocacy organization.   "More than one million American adults live with type 1 diabetes, and many still, sadly, ration their insulin, due to the prohibitively high cost of this necessary medication," said Starr.  "Civica's work will help to make insulin more affordable for people across the country."   Breakthrough T1D is among more than two dozen organizations and philanthropists, along with the states of Virginia and California, that have partnered with Civica to support the development of affordable insulins.   Civica's insulin initiative aims to provide patients with predictable, transparent pricing — no more than $30 per vial or $55 for a box of five pens — regardless of insurance status.   About Civica Civica is a nonprofit pharmaceutical company established to address drug shortages. It was founded by a group of U.S. health systems and philanthropies who, after more than a decade of chronic shortages, recognized that the market was not self-correcting and that a different approach is required. Civica works to deliver a safe, stable, and affordable supply of essential medicines to U.S. patients.   Media Contact: Liz Power liz.power@civicarx.org +1 860 501 3849 https://cbs4indy.com/business/press-releases/cision/20250807NY46213/governor-glenn-youngkin-announces-3-million-grant-to-support-civicas-affordable-insulin-programs/ XX If you or someone you love is living with diabetes, you already know the fight isn't just medical—it's financial, too. Between daily supplies, doctor visits, and long-term care, the cost of managing type 1 or type 2 diabetes can be overwhelming. Add college or trade school into the equation, and suddenly staying healthy competes with building a future. That's where scholarships for students with diabetes—like Beyond Scholars and others listed here—step in.   Whether you're headed to a university, a two-year college, or a hands-on trade program, these opportunities were created to ease the load.   Scholarships for students with diabetes Beyond Scholars (from Beyond Type 1): $10,000 for recently graduated high school seniors with type 1 diabetes or type 2 diabetes entering college or trade school. This is one of the largest needs-based diabetes scholarships in the United States. This year, awardees will also receive 6 months of wellness coaching through Risely Health.   Applications open: July 25, 2025 Deadline: August 29, 2025 Winners announced: October 2025 https://beyondtype1.org/beyond-scholars-diabetes-scholarships-college-trade-school/ XX Nick Jonas and Kyle Rudolph are using their platforms for a good cause.   On Tuesday, Aug. 12, the singer and the former NFL tight end (via his professional fundraising platform Alltroo) announced they're teaming up to launch a rally featuring a fan-coveted prize: a custom 2025 Volkswagen ID. Buzz electric bus that the Jonas Brothers have brought along for their 20th anniversary tour.   “Ten years ago, we hit the road with a goal to change what it means to live with diabetes. Since then, Beyond Type 1 has grown into the world's largest digital diabetes community, offering the tools, education, and peer support needed to not only survive but thrive with diabetes,” Jonas, who co-founded Beyond Type 1 (a nonprofit that advocates for those living with diabetes), says in a statement.     “We've challenged stigma, built community, provided life-saving resources, and collectively driven global innovation toward prevention and cure. This milestone is a moment to rally even more support for our mission, and partnering with Alltroo helps us do that in a powerful, engaging way.”   Related Stories Nick Jonas on Managing His Diabetes: 'The Mental and Emotional Health Aspect Is Really Important' nick jonas Nick Jonas Says He Was Diagnosed with Diabetes After Joe Told Their Parents: 'Something's Really Wrong' Joe Jonas and Nick Jonas attend the amfAR Cannes Gala 30th edition at Hotel du Cap-Eden-Roc on May 23, 2024 For Rudolph, the campaign is about "celebrating Beyond Type 1's incredible work over the past decade, and standing behind their vision of a world where everyone with diabetes — or at risk of it — has access to the knowledge, care and support needed for early diagnosis and lifelong health."   While the rally is live on Alltroo.com, fans can also scan QR codes available at all 36 Jonas Brothers concert stops to enter for a chance to win the electric bus. (A winner will be selected on November 14, which is World Diabetes Day.)   Jonas, 32, has long been open about his Type 1 diabetes diagnosis at 13 years old. "I had this kind of wrench thrown into things when I was diagnosed and it took a while to figure out how to count carbs to properly dose for insulin and what things would affect me in different ways," he previously told PEOPLE.   "When I was first diagnosed, I was sitting in the hospital and was scared to death, honestly, while I was learning about how to manage this new thing I was dealing with," Jonas recalled. "It would have been amazing to have someone to look at at that time to say, oh, this is a person living with it and they're following their dreams. They're doing what they want to do with their lives and not letting it slow them down."           https://people.com/nick-jonas-kyle-rudolph-launch-fan-rally-diabetes-awareness-11788684

Triforce! Episode 327! Pyrion creates a vicious The Platform-esque utopian society for pigeons, shares his story of getting onto the weight loss drug Mounjaro and shares some amazing stories of the greatest con artists! Support your favourite podcast on Patreon: https://bit.ly/2SMnzk6 Music courtesy of Epidemic Sound. Learn more about your ad choices. Visit podcastchoices.com/adchoices